GIP / GLP-1 receptor agonist

Tirzepatide

One of the strongest body-composition benchmarks in modern obesity medicine.

M5 Evidence Maturity · Established

Approved · indication-specific

Evidence reviewed: September 19, 2026Peer-reviewed DXA substudy

Signal summary

Tirzepatide is unusually valuable for body-composition analysis because the SURMOUNT-1 program includes direct DXA data rather than only scale weight.

Signal interpretation: Tirzepatide is a reference-quality composition card because it gives us direct fat/lean measurements. It demonstrates why a large scale-weight change should be broken into tissue compartments rather than treated as one number.

Study details

Doses studied — not a dosing recommendation. Regimens belong to the named study, formulation and population.

SURMOUNT-1 DXA substudy

Population: Adults with overweight/obesity without diabetes; 160 with baseline and end-of-study DXA.
Doses and administration studied: 5, 10 or 15 mg subcutaneously once weekly; gradual escalation in the parent trial. Composition results pooled the active doses.
Duration: 72 weeks
Reported finding / status: Pooled changes: body weight -21.3%, fat mass -33.9%, lean mass -10.9%. Approximately 75% of lost weight was fat and 25% lean tissue.
Interpretation and limitations: Pooled DXA findings are not dose-specific muscle-preservation estimates. DXA lean mass includes non-muscle tissue.

Source tier B · Read the original study or record

Outcome Evidence Strength

Weight change5/5

Fat-mass change3/5

Lean-mass change3/5

Strength / function benefit0/5

Weight: mature randomized obesity evidence. Fat and lean: published randomized DXA substudy. Function: this substudy does not establish a benefit.

Editorial evidence ratings for the cited outcomes, not effect size or treatment recommendations. A lean-mass score may describe loss. 0 means not established in the reviewed evidence, not proof of no effect. Read the rubric.

What is actually established?

At 72 weeks in the SURMOUNT-1 DXA substudy, body weight fell 21.3%, fat mass 33.9%, and lean mass 10.9% in the pooled tirzepatide group.
About 75% of the lost weight was fat mass and about 25% was lean mass.
The study provides direct evidence that substantial fat loss can occur alongside an absolute decline in lean mass.

What is not established?

DXA lean mass is not identical to skeletal muscle mass.
The substudy does not prove that tirzepatide uniquely preserves or harms muscle compared with every other therapy.
Long-term function and strength outcomes require separate evidence.

Still being studied

Long-term functional significance, subgroup differences and direct active-comparator body-composition outcomes.

Best human evidence at a glance

Evidence	Population	Comparator & duration	Outcome measured	Evidence state
SURMOUNT-1 DXA substudy	Adults with obesity or overweight in a randomized obesity trial	Placebo · 72 weeks	Scale weight, total fat mass and total lean mass	Peer-reviewed Direct composition evidence; function requires separate study.

Measurement context: DXA provides direct fat- and lean-mass estimates, but DXA lean mass is not synonymous with skeletal muscle quality, strength or function.

Safety evidence context

Clinical and regulatory safety evidence is mature for approved indications. Consult the current official label and a qualified clinician for risks, contraindications and individual decisions.

Interpretation boundary

This card describes population-level evidence and does not recommend a therapy, dose or protocol.

Sep 11, 2026

What changed: Added maturity-versus-outcome definitions, study context, measurement limitations and related comparison media.

Related comparisonVideo

Semaglutide vs Tirzepatide: what actually differs?

The comparison keeps trial context and body-composition evidence separate from headline percentages.

Open the comparison

Evidence sources

A = regulatory/official • B = peer-reviewed randomized/meta-analysis • C = peer-reviewed review/observational • D = registered trial • E = sponsor-reported • F = preclinical

Source tier B: Peer-reviewed DXA substudy
Body composition changes during weight reduction with tirzepatide in SURMOUNT-1

Source tier A: FDA regulatory record
Zepbound approval history, labels and reviews

Educational use only. This page summarizes research evidence and regulatory status. Study doses describe research, not prescribing instructions. This page does not provide personalized dosing, self-use protocols, sourcing, or a recommendation to use this therapy.